Enzymatic crosslinking and degradation of gelatin as a switch for bone morphogenetic protein-2 activity

Tissue Engineering - Part A

Volumn 17, Issue 23-24, 2011, Pages 2955-2964

  Kuwahara, Kenrick ^a   Fang, Josephine Y ^b   Yang, Zhi ^b   Han, Bo ^b  

^a Department of Biomedical Engineering University of Southern California ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDES; PHYSIOLOGY; REPAIR; TISSUE;

ADVERSE EFFECT; BONE FORMATION; BONE MORPHOGENETIC PROTEIN-2; COLLAGENASE; COVALENTLY BOUND; DELIVERY METHODS; DIFFUSIVE PROPERTIES; ENZYMATIC CROSSLINKING; GROWTH FACTOR; HIGH DOSE; MATRIX METALLOPROTEINASES; MICROBIAL TRANSGLUTAMINASE; ORDERS OF MAGNITUDE; PHYSIOLOGICAL LEVELS; PROTEASE ACTIVITIES; SITE-SPECIFIC; SPINAL FUSION; TIME-DEPENDENT; TISSUE REGENERATION; TISSUE REPAIR;

BONE;

BONE MORPHOGENETIC PROTEIN 2; COLLAGENASE; CROSS LINKING REAGENT; ENZYME; GELATIN; MATRIX METALLOPROTEINASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; BONE; BONE DEVELOPMENT; CELL LINE; CHORISTOMA; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; MOUSE; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEGRADATION; RAT; STREPTOMYCES; TIME;

ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEIN 2; CELL LINE; CHORISTOMA; COLLAGENASES; CROSS-LINKING REAGENTS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ACTIVATION; ENZYMES; GELATIN; MATRIX METALLOPROTEINASES; MICE; MODELS, BIOLOGICAL; OSTEOGENESIS; PROTEOLYSIS; RATS; STREPTOMYCES; TIME FACTORS; TRANSGLUTAMINASES;

EID: 82355171769     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2011.0290     Document Type: Article

References (69)

1. Kugimiya, F., Kawaguchi, H., Kamekura, S., Chikuda, H., Ohba, S., Yano, F., Ogata, N., Katagiri, T., Harada, Y., Azuma, Y., Nakamura, K., and Chung, U.I. Involvement of endogenous bone morphogenetic protein (BMP) 2 and BMP6 in bone formation. J Biol Chem 280, 35704, 2005.
2. Urist, M.R. Bone: formation by autoinduction. Science 150, 893, 1965.
3. Wang, E.A., Israel, D.I., Kelly, S., and Luxenberg, D.P. Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors 9, 57, 1993.
4. Suzawa, M., Takeuchi, Y., Fukumoto, S., Kato, S., Ueno, N., Miyazono, K., Matsumoto, T., and Fujita, T. Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. Endocrinology 140, 2125, 1999.
5. Katagiri, T., Yamaguchi, A., Komaki, M., Abe, E., Takahashi, N., Ikeda, T., Rosen, V., Wozney, J.M., Fujisawa-Sehara, A., and Suda, T. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 127, 1755, 1994.
6. Yamaguchi, A., Katagiri, T., Ikeda, T., Wozney, J.M., Rosen, V., Wang, E.A., Kahn, A.J., Suda, T., and Yoshiki, S. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol 113, 681, 1991.
7. Otsuru, S., Tamai, K., Yamazaki, T., Yoshikawa, H., and Kaneda, Y. Circulating bone marrow-derived osteoblast progenitor cells are recruited to the bone-forming site by the CXCR4/stromal cell-derived factor-1 pathway. Stem Cells 26, 223, 2008.
8. Sampath, T.K., Maliakal, J.C., Hauschka, P.V., Jones, W.K., Sasak, H., Tucker, R.F., White, K.H., Coughlin, J.E., Tucker, M.M., Pang, R.H., et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J Biol Chem 267, 20352, 1992.
9. Wang, E.A., Rosen, V., D'Alessandro, J.S., Bauduy, M., Cordes, P., Harada, T., Israel, D.I., Hewick, R.M., Kerns, K.M., LaPan, P., et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 87, 2220, 1990.
10. Burkus, J.K., Sandhu, H.S., Gornet, M.F., and Longley, M.C. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am 87, 1205, 2005.
11. Vaccaro, A.R., Anderson, D.G., Patel, T., Fischgrund, J., Truumees, E., Herkowitz, H.N., Phillips, F., Hilibrand, A., Albert, T.J., Wetzel, T., and McCulloch, J.A. Comparison of OP-1 Putty (rhBMP-7) to iliac crest autograft for posterolateral lumbar arthrodesis: a minimum 2-year follow-up pilot study. Spine (Phila Pa 1976) 30, 2709, 2005.
12. Carlisle, E., and Fischgrund, J.S. Bone morphogenetic proteins for spinal fusion. Spine J 5, 240S, 2005.
13. Braddock, M., Houston, P., Campbell, C., and Ashcroft, P. Born again bone: tissue engineering for bone repair. News Physiol Sci 16, 208, 2001.
14. Yamamoto, M., Takahashi, Y., and Tabata, Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 24, 4375, 2003.
15. Yamamoto, M., Tabata, Y., and Ikada, Y. Ectopic bone formation induced by biodegradable hydrogels incorporating bone morphogenetic protein. J Biomater Sci Polym Ed 9, 439, 1998.
16. Yang, S.H., Hsu, C.K., Wang, K.C., Hou, S.M., and Lin, F.H. Tricalcium phosphate and glutaraldehyde crosslinked gelatin incorporating bone morphogenetic protein-A viable scaffold for bone tissue engineering. J Biomed Mater Res B Appl Biomater 74, 468, 2005.
17. Seeherman, H., and Wozney, J.M. Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev 16, 329, 2005.
18. Kempen,D.H., Lu, L., Hefferan, T.E., Creemers, L.B.,Maran,A., Classic, K.L., Dhert, W.J., and Yaszemski, M.J. Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials 29, 3245, 2008.
19. Kim, H.D., and Valentini, R.F. Retention and activity of BMP-2 in hyaluronic acid-based scaffolds in vitro. J Biomed Mater Res 59, 573, 2002.
20. Nie, H., Soh, B.W., Fu, Y.C., and Wang, C.H. Threedimensional fibrous PLGA/HAp composite scaffold for BMP-2 delivery. Biotechnol Bioeng 99, 223, 2008.
21. Rengachary, S.S. Bone morphogenetic proteins: basic concepts. Neurosurg Focus 13, e2, 2002.
22. Luginbuehl, V., Meinel, L., Merkle, H.P., and Gander, B. Localized delivery of growth factors for bone repair. Eur J Pharm Biopharm 58, 197, 2004.
23. Rosen, V. BMP and BMP inhibitors in bone. Ann N Y Acad Sci 1068, 19, 2006.
24. Toth, J.M., Boden, S.D., Burkus, J.K., Badura, J.M., Peckham, S.M., and McKay, W.F. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine (Phila Pa 1976) 34, 539, 2009.
25. Liu, Y., Enggist, L., Kuffer, A.F., Buser, D., and Hunziker, E.B. The influence of BMP-2 and its mode of delivery on the osteoconductivity of implant surfaces during the early phase of osseointegration. Biomaterials 28, 2677, 2007.
26. Tuan, T.L., Cheung, D.T., Wu, L.T., Yee, A., Gabriel, S., Han, B., Morton, L., Nimni, M.E., and Hall, F.L. Engineering, expression and renaturation of targeted TGF-beta fusion proteins. Connect Tissue Res 34, 1, 1996.
27. Han, B., Hall, F.L., and Nimni, M.E. Refolding of a recombinant collagen-targeted TGF-beta2 fusion protein expressed in Escherichia coli. Protein Expr Purif 11, 169, 1997.
28. Han, B., Perelman, N., Tang, B., Hall, F., Shors, E.C., and Nimni, M.E. Collagen-targeted BMP3 fusion proteins arrayed on collagen matrices or porous ceramics impregnated with Type I collagen enhance osteogenesis in a rat cranial defect model. J Orthop Res 20, 747, 2002.
29. Hall, F.L., Han, B., Kundu, R.K., Yee, A., Nimni, M.E., and Gordon, E.M. Phenotypic differentiation of TGF-beta1-responsive pluripotent premesenchymal prehematopoietic progenitor (P4 stem) cells from murine bone marrow. J Hematother Stem Cell Res 10, 261, 2001.
30. Andrades, J.A., Han, B., Nimni, M.E., Ertl, D.C., Simpkins, R.J., Arrabal, M.P., and Becerra, J. A modified rhTGF-beta1 and rhBMP-2 are effective in initiating a chondro-osseous differentiation pathway in bone marrow cells cultured in vitro. Connect Tissue Res 44, 188, 2003.
31. Liu, H.W., Chen, C.H., Tsai, C.L., and Hsiue, G.H. Targeted delivery system for juxtacrine signaling growth factor based on rhBMP-2-mediated carrier-protein conjugation. Bone 39, 825, 2006.
32. Schmoekel, H.G., Weber, F.E., Schense, J.C., Gratz, K.W., Schawalder, P., and Hubbell, J.A. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol Bioeng 89, 253, 2005.
33. Tabata, Y. Tissue regeneration based on tissue engineering technology. Congenit Anom (Kyoto) 44, 111, 2004.
34. Tabata, Y., Hijikata, S., and Ikada, Y. Enhanced vascularization and tissue granulation by basic fibroblast growth factor impregnated in gelatin hydrogels. J Controlled Release 31, 189, 1994.
35. Ferreira, J.P., Sasisekharan, R., Louie, O., and Langer, R. A study on the functional subunits of phospholipases A2 by enzyme immobilization. Biochem J 303 (Pt 2), 527, 1994.
36. Tsujigiwa, H., Nagatsuka, H., Gunduz, M., Rodriguez, A., Rivera, R.S., Legeros, R.Z., Inoue, M., and Nagai, N. Effects of immobilized recombinant human bone morphogenetic protein-2/succinylated type I atelocollagen on cellular activity of ST2 cells. J Biomed Mater Res A 75, 210, 2005.
37. Ehrbar, M., Rizzi, S.C., Hlushchuk, R., Djonov, V., Zisch, A.H., Hubbell, J.A., Weber, F.E., and Lutolf, M.P. Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering. Biomaterials 28, 3856, 2007.
38. Demolliens, A., Boucher, C., Durocher, Y., Jolicoeur, M., Buschmann, M.D., and De Crescenzo, G. Tyrosinasecatalyzed synthesis of a universal coil-chitosan bioconjugate for protein immobilization. Bioconjug Chem 19, 1849, 2008.
39. Scuderi, N., Onesti, M.G., Bistoni, G., Ceccarelli, S., Rotolo, S., Angeloni, A., and Marchese, C. The clinical application of autologous bioengineered skin based on a hyaluronic acid scaffold. Biomaterials 29, 1620, 2008.
40. Ehrbar, M., Zeisberger, S.M., Raeber, G.P., Hubbell, J.A., Schnell, C., and Zisch, A.H. The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials 29, 1720, 2008.
41. Sakiyama-Elbert, S.E., Panitch, A., and Hubbell, J.A. Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J 15, 1300, 2001.
42. Kuwahara, K., Yang, Z., Slack, G.C., Nimni,M.E., and Han, B. Cell delivery using an injectable and adhesive transglutaminase-gelatin gel. Tissue Eng Part C Methods 16, 609, 2010.
43. Bertoni, F., Barbani, N., Giusti, P., and Ciardelli, G. Transglutaminase reactivity with gelatine: perspective applications in tissue engineering. Biotechnol Lett 28, 697, 2006.
44. Ito, A., Mase, A., Takizawa, Y., Shinkai, M., Honda, H., Hata, K., Ueda, M., and Kobayashi, T. Transglutaminase-mediated gelatin matrices incorporating cell adhesion factors as a biomaterial for tissue engineering. J Biosci Bioeng 95, 196, 2003.
45. Yung, C.W., Wu, L.Q., Tullman, J.A., Payne, G.F., Bentley, W.E., and Barbari, T.A. Transglutaminase crosslinked gela-tin as a tissue engineering scaffold. J Biomed Mater Res A 83, 1039, 2007.
46. Chen, R.N., Ho, H.O., and Sheu, M.T. Characterization of collagen matrices crosslinked using microbial transglutaminase. Biomaterials 26, 4229, 2005.
47. Chau, D.Y., Collighan, R.J., Verderio, E.A., Addy, V.L., and Griffin, M. The cellular response to transglutaminase-crosslinked collagen. Biomaterials 26, 6518, 2005.
48. Han, Y.P., Tuan, T.L., Wu, H., Hughes, M., and Garner, W.L. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J Cell Sci 114, 131, 2001.
49. Han, B., Tang, B., and Nimni, M.E. Quantitative and sensitive in vitro assay for osteoinductive activity of demineralized bone matrix. J Orthop Res 21, 648, 2003.
50. Gobin, A.S., and West, J.L. Effects of epidermal growth factor on fibroblast migration through biomimetic hydrogels. Biotechnol Prog 19, 1781, 2003.
51. Folk, J.E. Mechanism and basis for specificity of transglutaminase- catalyzed epsilon-(gamma-glutamyl) lysine bond formation. Adv Enzymol Relat Areas Mol Biol 54, 1, 1983.
52. Fontana, A., Spolaore, B., Mero, A., and Veronese, F.M. Sitespecific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev 60, 13, 2008.
53. Kahlem, P., Terre, C., Green, H., and Djian, P. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc Natl Acad Sci USA 93, 14580, 1996.
54. Ohtsuka, T., Ota, M., Nio, N., and Motoki, M. Comparison of substrate specificities of transglutaminases using synthetic peptides as acyl donors. Biosci Biotechnol Biochem 64, 2608, 2000.
55. Taguchi, S., Nishihama, K.I., Igi, K., Ito, K., Taira, H., Motoki, M., and Momose, H. Substrate specificity analysis of microbial transglutaminase using proteinaceous protease inhibitors as natural model substrates. J Biochem 128, 415, 2000.
56. Nickel, J., Dreyer, M.K., Kirsch, T., and Sebald, W. The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists. J Bone Joint Surg Am 83-A Suppl 1, S7, 2001.
57. Namiki, M., Akiyama, S., Katagiri, T., Suzuki, A., Ueno, N., Yamaji, N., Rosen, V., Wozney, J.M., and Suda, T. A kinase domain-truncated type I receptor blocks bone morphogenetic protein-2-induced signal transduction in C2C12 myoblasts. J Biol Chem 272, 22046, 1997.
58. Kirsch, T., Nickel, J., and Sebald, W. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J 19, 3314, 2000.
59. Lutolf, M.P., Lauer-Fields, J.L., Schmoekel, H.G., Metters, A.T., Weber, F.E., Fields, G.B., and Hubbell, J.A. Synthetic matrix metalloproteinase- sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc Natl Acad Sci USA 100, 5413, 2003.
60. Lutolf, M.P., Weber, F.E., Schmoekel, H.G., Schense, J.C., Kohler, T., Muller, R., and Hubbell, J.A. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol 21, 513, 2003.
61. Seliktar, D., Zisch, A.H., Lutolf, M.P., Wrana, J.L., and Hubbell, J.A. MMP-2 sensitive, VEGF-bearing bioactive hydrogels for promotion of vascular healing. J Biomed Mater Res A 68, 704, 2004.
62. Kraehenbuehl, T.P., Ferreira, L.S., Zammaretti, P., Hubbell, J.A., and Langer, R. Cell-responsive hydrogel for encapsulation of vascular cells. Biomaterials 30, 4318, 2009.
63. Raeber, G.P., Lutolf, M.P., and Hubbell, J.A. Mechanisms of 3-D migration and matrix remodeling of fibroblasts within artificial ECMs. Acta Biomater 3, 615, 2007.
64. Zisch, A.H., Lutolf, M.P., Ehrbar, M., Raeber, G.P., Rizzi, S.C., Davies, N., Schmokel, H., Bezuidenhout, D., Djonov, V., Zilla, P., and Hubbell, J.A. Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J 17, 2260, 2003.
65. Lluri, G., and Jaworski, D.M. Regulation of TIMP-2, MT1-MMP, and MMP-2 expression during C2C12 differentiation. Muscle Nerve 32, 492, 2005.
66. Blumenfeld, I., Srouji, S., Peled, M., and Livne, E. Metalloproteinases (MMPs-2,-3) are involved in TGF-beta and IGF-1-induced bone defect healing in 20-month-old female rats. Arch Gerontol Geriatr 35, 59, 2002.
67. Kinoh, H., Sato, H., Tsunezuka, Y., Takino, T., Kawashima, A., Okada, Y., and Seiki, M. MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci 109 (Pt 5), 953, 1996.
68. Murphy, G., and Lee, M.H. What are the roles of metalloproteinases in cartilage and bone damage? Ann Rheum Dis 64 Suppl 4, iv44, 2005.
69. Orban, J.M., Wilson, L.B., Kofroth, J.A., El-Kurdi, M.S., Maul, T.M., and Vorp, D.A. Crosslinking of collagen gels by transglutaminase. J Biomed Mater Res A 68, 756, 2004.